Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 31;141(17):1371–1383. doi: 10.1161/CIRCULATIONAHA.119.044366

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

PMC Copyright notice

Figure 3. — Forest plot depicting risk predictors for developing the composite outcome of all-cause mortality, cardiac transplantation (Tx), or left ventricular assist device (VAD) implantation in 394 genotyped patients with hypertrophic cardiomyopathy with left ventricular systolic dysfunction (HCM-LVSD) experiencing 136 composite events. Unadjusted number of events per variable is shown in the second column. Hazard ratios are adjusted for all included risk factors. The diamond symbol in the cohort with ≥1 pathogenic/likely pathogenic variant (SARC+) represents the composite effect of thin filament, thick filament, and multiple pathogenic/likely pathogenic (P/LP) sarcomere variants. LVEF indicates left ventricular ejection fraction; LVIDd, left ventricular diastolic diameter; NYHA, New York Heart Association; ref, referent; SARC−, no clinically relevant sarcomere variants identified on genetic testing; and SARC VUS, a variant of unknown significance in a sarcomere gene.